Last reviewed · How we verify
Sabin Strain Inactivated Poliovirus Vaccine
Sabin Strain Inactivated Poliovirus Vaccine is a Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently in Phase 3 development for Prevention of poliomyelitis.
The Sabin Strain Inactivated Poliovirus Vaccine works by exposing the body to a weakened form of the poliovirus, stimulating an immune response to provide protection against poliovirus infection.
The Sabin Strain Inactivated Poliovirus Vaccine works by exposing the body to a weakened form of the poliovirus, stimulating an immune response to provide protection against poliovirus infection. Used for Prevention of poliomyelitis.
At a glance
| Generic name | Sabin Strain Inactivated Poliovirus Vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains inactivated poliovirus strains, which are unable to cause disease but can still trigger an immune response. The immune system recognizes the inactivated virus as foreign and mounts a response to eliminate it, providing immunity against future poliovirus infections.
Approved indications
- Prevention of poliomyelitis
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (PHASE3)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074) (PHASE3)
- Phase IV Study of Concomitant Administration of the sIPV and HepA (PHASE4)
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sabin Strain Inactivated Poliovirus Vaccine CI brief — competitive landscape report
- Sabin Strain Inactivated Poliovirus Vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about Sabin Strain Inactivated Poliovirus Vaccine
What is Sabin Strain Inactivated Poliovirus Vaccine?
How does Sabin Strain Inactivated Poliovirus Vaccine work?
What is Sabin Strain Inactivated Poliovirus Vaccine used for?
Who makes Sabin Strain Inactivated Poliovirus Vaccine?
What development phase is Sabin Strain Inactivated Poliovirus Vaccine in?
What are the side effects of Sabin Strain Inactivated Poliovirus Vaccine?
Related
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of poliomyelitis
- Compare: Sabin Strain Inactivated Poliovirus Vaccine vs similar drugs
- Pricing: Sabin Strain Inactivated Poliovirus Vaccine cost, discount & access